Incidence of severe urinary tract infections not increased by initiating sodium ‐glucose cotransporter‐2 inhibitors

AbstractRecently, the Food and Drug Administration (FDA) issued an advisory that sodium ‐glucose cotransporter‐2 (SGLT‐2) inhibitors are associated with a risk of severe urinary tract infection (UTI) (1). They reported 19 patients with life‐threatening sepsis due to UTI and severe pyelonephritis after initiating SGLT‐2 inhibitors who required hospitalization. Some of them req uired admission to an intensive care unit or dialysis in order to treat acute renal failure.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Commentary Source Type: research